Alnylam Pharmaceuticals, Inc. vs Blackstone Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Blackstone Inc trades at $147.21 (market cap $117.44B). The key difference: Blackstone Inc is far larger — about 4× Alnylam Pharmaceuticals, Inc.'s market cap, and Blackstone Inc pays a 3.55% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BX | |
|---|---|---|
Market Cap | $29.60B | $117.44B |
Sector | Health | Financials |
52-Week High | $491.22 | $188.68 |
52-Week Low | $205.48 | $102.12 |
Enterprise Value | $27.56B | — |
Dividend Yield | — | 3.55% |
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Blackstone (BX) trades at $146.44, up 3.37% today, near its recent high. The stock shows strong earnings momentum with three consecutive quarterly beats and a robust 25.85% net income margin. Technical indicators are bullish overall, though RSI levels suggest potential overbought conditions. Recent corporate activity includes a $2.5 billion investment in Air Canada's Aeroplan loyalty program, highlighting aggressive growth initiatives.
The outlook remains positive given consistent earnings outperformance and strategic acquisitions. Key risks include market sensitivity to private equity cycles and high valuation multiples. With a consensus price target of $144.00 and 63% analyst buy ratings, Wall Street sentiment is bullish, but investors should monitor execution on large deals and broader economic trends.
Trailing returns across standard periods
Latest headlines on both assets
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.
Read more on BX →